Melfalan Amarox (Melphalan Hydrochloride)

Melphalan hydrochloride belongs to the nitrogen‑mustard class of alkylating agents. It forms covalent bonds with DNA, creating cross‑links that block DNA replication and transcription. The resulting damage triggers cell‑cycle arrest and apoptosis, especially in rapidly dividing cancer cells.

The dose of Melfalan Amarox is individualized by the treating oncologist based on factors such as the specific cancer type, disease stage, patient weight, renal and hepatic function, and prior treatment history. No fixed dosing schedule is provided in public literature.

Safety data for melphalan in pregnancy and lactation are limited, and the drug is generally considered contraindicated because of potential fetal toxicity and excretion in breast milk. Use is only considered if the potential benefit justifies the risk and after specialist consultation.

To order Melfalan Amarox, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Melfalan Amarox (melphalan) is a nitrogen‑mustard alkylator similar to cyclophosphamide and ifosfamide but differs in its chemical structure and spectrum of activity. It is often preferred for high‑dose regimens in multiple myeloma and certain solid tumours because of its potent DNA‑cross‑linking ability, though it may have a higher risk of specific toxicities such as secondary leukaemia.

Melfalan Amarox should be stored refrigerated at 2‑8 °C. The product must be kept in its original container, protected from light, and should never be frozen or shaken. If the solution is prepared for immediate use, it should be administered promptly and any unused portion discarded according to local regulations.

Melfalan Amarox is supplied as a sterile solution for intravenous or intra‑arterial infusion. The infusion is typically given over a defined period under medical supervision, with dosing calculated by the prescribing physician. Infusion rates and pre‑medication (e.g., anti‑emetics) are adjusted based on patient tolerance and clinical protocol.

The most serious risks include severe bone‑marrow suppression leading to neutropenia, anemia or thrombocytopenia, which can cause life‑threatening infections or bleeding; secondary leukaemia or myelodysplastic syndrome; renal toxicity; pulmonary fibrosis; and rare but severe allergic reactions such as anaphylaxis.

Melfalan Amarox is contraindicated in patients with known hypersensitivity to melphalan or other nitrogen‑mustard agents, in those with uncontrolled infections, severe renal or hepatic impairment, and in pregnant or nursing women unless the therapeutic benefit outweighs the potential risk. Clinical judgment is required for patients with pre‑existing bone‑marrow disorders.